Assignee
NEUREN PHARMACEUTICALS LTD
NZ·23 granted patents·11 pending applications·1,564 citations·filing 1999–2025
Top patents by PatentIndex Score
34 records- 0194US7563862B2Neural regeneration peptides and methods for their use in treatment of brain damageNEUREN PHARMACEUTICALS LTD·Filed 2004·Granted Jul 21, 2009·1.5k cites·28 claims
- 0290US11370755B2Compositions of trofinetideNEUREN PHARMACEUTICALS LTD·Filed 2021·Granted Jun 28, 2022·4 cites·20 claims
- 0390US7714020B2Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamateNEUREN PHARMACEUTICALS LTD·Filed 2006·Granted May 11, 2010·18 cites·19 claims
- 0489US7605177B2Effects of glycyl-2 methyl prolyl glutamate on neurodegenerationNEUREN PHARMACEUTICALS LTD·Filed 2005·Granted Oct 20, 2009·14 cites·13 claims
- 0588US11866406B2Compositions of trofinetideNEUREN PHARMACEUTICALS LTD·Filed 2022·Granted Jan 9, 2024·2 cites·20 claims
- 0687US7887839B2Oral formulations of glycyl-2-methylprolyl-glutamateNEUREN PHARMACEUTICALS LTD·Filed 2008·Granted Feb 15, 2011·14 cites·15 claims
- 0786US9212204B2Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acidNEUREN PHARMACEUTICALS LTD·Filed 2015·Granted Dec 15, 2015·8 cites·7 claims
- 0884US7863304B2Analogs of glycyl-prolyl-glutamateNEUREN PHARMACEUTICALS LTD·Filed 2007·Granted Jan 4, 2011·8 cites·14 claims
- 0984US7776876B2Cyclic G-2Allylproline in treatment of Parkinson's diseaseNEUREN PHARMACEUTICALS LTD·Filed 2006·Granted Aug 17, 2010·6 cites·13 claims
- 1080US7041314B2GPE analogs and peptidomineticsNEUREN PHARMACEUTICALS LTD·Filed 2002·Granted May 9, 2006·13 cites·16 claims
- 1177US9867823B2Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disordersNEUREN PHARMACEUTICALS LTD·Filed 2016·Granted Jan 16, 2018·3 cites·19 claims
- 1273US12297172B2Compositions of trofinetideNEUREN PHARMACEUTICALS LTD·Filed 2023·Granted May 13, 2025·0 cites·15 claims
- 1367US9119851B2Cyclic Glycyl-2-Allyl Proline improves cognitive performance in impaired animalsNEUREN PHARMACEUTICALS LTD·Filed 2014·Granted Sep 1, 2015·0 cites·29 claims
- 1467US7767786B2Neural regeneration peptides and methods for their use in treatment of neural injury or degenerationNEUREN PHARMACEUTICALS LTD·Filed 2002·Granted Aug 3, 2010·3 cites·4 claims
- 1565US6933282B2Regulation of tyrosine hydroxylase by GPENEUREN PHARMACEUTICALS LTD·Filed 2003·Granted Aug 23, 2005·2 cites·15 claims
- 1661US11197856B2Bicyclic compounds and methods for their use in treating autismNEUREN PHARMACEUTICALS LTD·Filed 2020·Granted Dec 14, 2021·0 cites·24 claims
- 1761US2007015707A1Neuroprotective effect of activin in animals exposed to hypoxia/ischemiaNEUREN PHARMACEUTICALS LTD·Filed 2006·Application pending·0 cites
- 1861US2025367192A1Bicyclic compounds and methods for their use in treating pitt hopkins syndromeNEUREN PHARMACEUTICALS LTD·Filed 2025·Application pending·0 cites
- 1958US2026001882A1Process for preparing bicyclic glycine-proline compounds and monocyclic glycine-proline intermediates thereofNEUREN PHARMACEUTICALS LTD·Filed 2022·Application pending·0 cites
- 2056US10548892B2Bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disordersNEUREN PHARMACEUTICALS LTD·Filed 2018·Granted Feb 4, 2020·0 cites·30 claims
- 2155US7485630B2Neuroprotective macrocyclic compounds and methods for their useNEUREN PHARMACEUTICALS LTD·Filed 2004·Granted Feb 3, 2009·0 cites·15 claims
- 2254US2015258091A1Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animalsNEUREN PHARMACEUTICALS LTD·Filed 2015·Application pending·0 cites
- 2354US2009304700A1Conformation specific antibodies that bind trefoil factorsNEUREN PHARMACEUTICALS LTD·Filed 2009·Application pending·0 cites
- 2451US7112570B2GPE analogsNEUREN PHARMACEUTICALS LTD·Filed 2001·Granted Sep 26, 2006·0 cites·21 claims
- 2549US2024132511A1Treatments of prader-willi syndromeNEUREN PHARMACEUTICALS LTD·Filed 2022·Application pending·0 cites
- 2649US2007004641A1Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamateNEUREN PHARMACEUTICALS LTD·Filed 2005·Application pending·0 cites
- 2748US12472177B2Bicyclic compounds and methods for their use in treating Pitt Hopkins syndromeNEUREN PHARMACEUTICALS LTD·Filed 2020·Granted Nov 18, 2025·0 cites·18 claims
- 2848US7282342B2Methods for detecting weakly immunogenic analytesNEUREN PHARMACEUTICALS LTD·Filed 2006·Granted Oct 16, 2007·0 cites·15 claims
- 2947US2006035279A1Anti-GPE antibodies, their uses and assays for weakly immunogenic moleculesNEUREN PHARMACEUTICALS LTD·Filed 2004·Application pending·0 cites
- 3043US2007224165A1Neuroprotective Effects of Gly-Pro-Glu Following Intravenous InfusionNEUREN PHARMACEUTICALS LTD·Filed 2004·Application pending·0 cites
- 3142US7192931B2Treatment of demyelinating diseasesNEUREN PHARMACEUTICALS LTD·Filed 2001·Granted Mar 20, 2007·0 cites·49 claims
- 3241US2006281675A1Somatogenic therapy using a 20kda placental variant of growth hormoneNEUREN PHARMACEUTICALS LTD·Filed 2004·Application pending·0 cites
- 3339US7304029B1Neuroprotective effect of growth hormoneNEUREN PHARMACEUTICALS LTD·Filed 1999·Granted Dec 4, 2007·4 cites·7 claims
- 3435US2015224164A1Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acidNEUREN PHARMACEUTICALS LTD·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when NEUREN PHARMACEUTICALS LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →